Monitor the upcoming annual meeting for vote outcomes, particularly the authorized share increase which could enable future dilutive financing. Trading impact is minimal as this is a routine procedural filing.
Price Chart
Executive Summary
Rein Therapeutics filed additional definitive proxy soliciting materials (DEFA14A) for its 2026 Annual Meeting of Stockholders to be held on July 20, 2026. The board recommends voting FOR the election of two Class III directors (Reinhard J. Ambros, Ph.D. and Josef H. von Rickenbach), an increase in authorized shares of common stock, ratification of CBIZ CPAs P.C. as auditor, and an advisory vote on executive compensation. This is a routine notice of meeting and proxy availability with no material financial data.
Key Financial Metrics
Key Facts
- Annual meeting scheduled for July 20, 2026
- Board recommends FOR election of two Class III directors: Reinhard J. Ambros, Ph.D. and Josef H. von Rickenbach
- Board recommends FOR proposal to increase authorized shares of common stock
- Board recommends FOR ratification of CBIZ CPAs P.C. as independent auditor
- Board recommends FOR advisory vote on named executive officer compensation
- Filing is a routine notice of proxy availability with no financial data disclosed
Financial Impact
No financial figures disclosed in this filing
Risk Factors
- Share increase proposal could lead to future dilution if authorized shares are issued
- No financial or operational updates provided in this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-260812 |
| Document: 0001193125-26-260812-index.html | 0001193125-26-260812 |
| Document: 0001193125-26-260812.txt | 0001193125-26-260812 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 7w ago | Press Release | $0.8891 | awaiting T+60 | — | $0.5820 (−34.54%) |
Aug 14, 2026 10w ago | Press Release | $0.8060 | awaiting T+60 | — | $0.5820 (−27.79%) |
Jul 21, 2026 13w ago | Press Release | $0.8948 $0.7546 | ▼ −15.67% | ▼ −19.64% | $0.5820 (−34.96%) |
Jun 8, 2026 20w ago | DEFA14A | $0.9487 $0.7527 | ▼ −20.66% | ▼ −23.71% | $0.5820 (−38.65%) |
May 4, 2026 25w ago | 8-K | $1.02 $0.7680 | ▲ +24.71% | ▲ +27.45% | $0.5820 (+42.94%) |
May 4, 2026 25w ago | 424B5 | $1.02 $0.7580 | ▲ +25.69% | ▲ +27.54% | $0.5820 (+42.94%) |
May 1, 2026 25w ago | Press Release | $1.03 $0.7818 | ▲ +24.10% | ▲ +27.17% | $0.5820 (+43.50%) |
Apr 29, 2026 25w ago | Press Release | $1.28 $0.7913 | ▼ −37.94% | ▼ −42.05% | $0.5820 (−54.35%) |
Apr 28, 2026 25w ago | S-1 | $1.28 $0.7913 | ▼ −37.94% | ▼ −42.05% | $0.5820 (−54.35%) |
Apr 27, 2026 26w ago | 10-K/A | $1.49 $0.8400 | ▼ −43.62% | ▼ −48.40% | $0.5820 (−60.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers